[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7529 Introduced in House (IH)]

<DOC>






117th CONGRESS
  2d Session
                                H. R. 7529

To require direct-to-consumer advertisements for prescription drugs and 
  biological products to include truthful and not misleading pricing 
                              information.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                             April 14, 2022

  Ms. Williams of Georgia (for herself, Mr. Bacon, Ms. Craig, and Mr. 
    Steil) introduced the following bill; which was referred to the 
 Committee on Energy and Commerce, and in addition to the Committee on 
   Ways and Means, for a period to be subsequently determined by the 
  Speaker, in each case for consideration of such provisions as fall 
           within the jurisdiction of the committee concerned

_______________________________________________________________________

                                 A BILL


 
To require direct-to-consumer advertisements for prescription drugs and 
  biological products to include truthful and not misleading pricing 
                              information.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Plain Prescription Prices Act''.

SEC. 2. REGULATING ADVERTISEMENTS FOR PRESCRIPTION DRUG AND BIOLOGICAL 
              PRODUCT PRICES.

    (a) In General.--Not later than one year after the date of the 
enactment of this Act, the Secretary of Health and Human Services, 
acting through the Administrator of the Centers for Medicare & Medicaid 
Services (referred to in this section as the ``Administrator''), shall 
promulgate regulations requiring each direct-to-consumer advertisement 
on television (including broadcast, cable, streaming, and satellite 
television) for a prescription drug or biological product for which 
payment is available under title XVIII or XIX of the Social Security 
Act to include a textual statement, which shall be truthful and not 
misleading, indicating the list price, as determined on the first day 
of the quarter during which the advertisement is being aired or 
otherwise broadcast, for a typical 30-day regimen or typical course of 
treatment (whichever is most appropriate).
    (b) Determinations.--In promulgating regulations under subsection 
(a), the Administrator shall determine--
            (1) whether such regulations should apply with respect to 
        additional forms of advertising;
            (2) the manner and format of textual statements described 
        in such subsection;
            (3) appropriate enforcement mechanisms; and
            (4) whether such textual statements should include any 
        other price information, as appropriate.
                                 <all>